Advances in end-to-end multiomics platforms and the underlying scientific knowledge now enable faster and more precise biomarker discovery, mechanistic insight generation, and therapeutic design—core drivers of modern drug discovery programs. Within this integrated ecosystem, mass spectrometry-based metabolomics serves as a central analytical modality, offering the ability to quantify large numbers of metabolites from a single sample with high sensitivity and rapid turnaround.
Metabolomics supports biochemical pathway-level interpretation, where a primary biomarker can be contextualized alongside upstream and downstream metabolites to inform target identification, pathway modulation, and pharmacodynamic response assessment. Rather than focusing solely on the discovery of novel metabolites, emerging approaches emphasize the identification of characteristic metabolic signatures that differentiate disease states, therapeutic responses, or mechanistic subtypes.
Realizing this potential requires the development and deployment of AI enabled data analysis workflows that can reduce interpretation time, expand the breadth of detectable targets, and uncover complex patterns of metabolite perturbation. These capabilities ultimately enhance the precision and effectiveness of targeted therapeutic development.
Taraka Donti, PhD, is director of lab services at Revvity Omics.
